Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Ice × 1 year × Clear all

Phase

Status

Terminated 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, T-Cell, Peripheral 1 Lymphoma, Extranodal NK-T-Cell 1

Interventions

pembrolizumab 100 Nivolumab 42 Carboplatin 40 Cyclophosphamide 39 venetoclax 29 Gemcitabine 29 Paclitaxel 27 atezolizumab 26 fludarabine 25 Cisplatin 25 Azacitidine 24 Docetaxel 22 Dexamethasone 22 Specimen Handling 21 Magnetic Resonance Spectroscopy 21 Bevacizumab 21 Biopsy 20 Radiotherapy 19 Pemetrexed 19 Rituximab 17 Fluorouracil 16 durvalumab 15 Leucovorin 15 Radiosurgery 14 Cytarabine 14 spartalizumab 13 Ipilimumab 12 Cetuximab 12 Capecitabine 12 tislelizumab 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04425070 2026-01-05

TOUCH

Antengene Corporation

Phase 1/2 Terminated

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡